NYSE:MED Medifast (MED) Stock Price, News & Analysis → Biden’s $374B Giveaway Into This Sector (From DTI) (Ad) Free MED Stock Alerts $32.59 +0.12 (+0.37%) (As of 10:33 AM ET) Add Compare Share Share Today's Range$32.26▼$32.9550-Day Range$31.35▼$56.2352-Week Range$30.95▼$109.52Volume35,493 shsAverage Volume378,597 shsMarket Capitalization$355.10 millionP/E Ratio3.58Dividend YieldN/APrice Target$61.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Medifast alerts: Email Address Medifast MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside87.7% Upside$61.00 Price TargetShort InterestBearish25.09% of Float Sold ShortDividend StrengthWeakBased on Four FactorsSustainability-4.07Upright™ Environmental ScoreNews Sentiment-0.35Based on 3 Articles This WeekInsider TradingSelling Shares$159,850 Sold Last QuarterProj. Earnings Growth40.45%From $3.56 to $5.00 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.90 out of 5 starsConsumer Staples Sector57th out of 136 stocksMiscellaneous Food Preparations & Kindred Products Industry2nd out of 4 stocks 3.0 Analyst's Opinion Consensus RatingMedifast has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageMedifast has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted25.09% of the float of Medifast has been sold short.Short Interest Ratio / Days to CoverMedifast has a short interest ratio ("days to cover") of 6.9.Change versus previous monthShort interest in Medifast has recently increased by 29.76%, indicating that investor sentiment is decreasing significantly. Previous Next 0.8 Dividend Strength Dividend YieldMedifast does not currently pay a dividend.Dividend GrowthMedifast has only been increasing its dividend for 1 years.Dividend CoverageThe dividend payout ratio of Medifast is 72.45%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on EPS estimates, Medifast will have a dividend payout ratio of 132.00% in the coming year. This indicates that Medifast may not be able to sustain their current dividend. Previous Next 1.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMedifast has received a -4.19% net impact score from Upright. The largest negative impact of Medifast in category "GHG emissions" seems to be driven mostly by its "Meal replacement soups", "Meal replacement bars", "Meal replacement drinks", and "Protein bars" products. See details.Environmental SustainabilityThe Environmental Impact score for Medifast is -4.07. Previous Next 0.9 News and Social Media Coverage News SentimentMedifast has a news sentiment score of -0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Consumer Staples companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Medifast this week, compared to 4 articles on an average week.Search InterestOnly 11 people have searched for MED on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Medifast to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Medifast insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $159,850.00 in company stock.Percentage Held by InsidersOnly 2.06% of the stock of Medifast is held by insiders.Percentage Held by Institutions95.51% of the stock of Medifast is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Medifast are expected to grow by 40.45% in the coming year, from $3.56 to $5.00 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Medifast is 3.57, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 133.06.Price to Earnings Ratio vs. SectorThe P/E ratio of Medifast is 3.57, which means that it is trading at a less expensive P/E ratio than the Consumer Staples sector average P/E ratio of about 16.67.Price to Book Value per Share RatioMedifast has a P/B Ratio of 1.76. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIBiden’s $374B Giveaway Into This SectorBiden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereClick here for the full story About Medifast Stock (NYSE:MED)Medifast, Inc., through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names. The company markets its products through point-of-sale transactions, as well as through ecommerce platform. Medifast, Inc. was founded in 1980 and is headquartered in Baltimore, Maryland.Read More MED Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MED Stock News HeadlinesMarch 19, 2024 | marketbeat.comLifeMD Shares Come Back to Life on GLP-1 Business Growth (MED)LifeMD stock is surging as the company is riding the GLP-1 trend to double-digit revenue growth and projections for 67% earnings growth in 2024April 16, 2024 | finance.yahoo.comHere’s Why Miller Income Strategy Sold Medifast (MED)April 19, 2024 | DTI (Ad)Biden’s $374B Giveaway Into This SectorBiden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereApril 15, 2024 | businesswire.comMedifast to Announce Financial Results for the First Quarter Ended March 31, 2024April 14, 2024 | finance.yahoo.comMedifast (NYSE:MED) investors are sitting on a loss of 85% if they invested three years agoApril 10, 2024 | finance.yahoo.comQ4 Earnings Highlights: Herbalife (NYSE:HLF) Vs The Rest Of The Personal Care StocksApril 8, 2024 | finance.yahoo.comPersonal Care Stocks Q4 Teardown: Coty (NYSE:COTY) Vs The RestApril 5, 2024 | finance.yahoo.comQ4 Earnings Roundup: Nu Skin (NYSE:NUS) And The Rest Of The Personal Care SegmentApril 19, 2024 | DTI (Ad)Biden’s $374B Giveaway Into This SectorBiden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereApril 4, 2024 | finance.yahoo.comSpotting Winners: Nature's Sunshine (NASDAQ:NATR) And Personal Care Stocks In Q4April 3, 2024 | finance.yahoo.comPersonal Care Stocks Q4 Teardown: e.l.f. (NYSE:ELF) Vs The RestApril 2, 2024 | finance.yahoo.comQ4 Personal Care Earnings Review: First Prize Goes to The Honest Company (NASDAQ:HNST)April 1, 2024 | benzinga.com(MED) - Analyzing Medifast's Short InterestMarch 28, 2024 | msn.comOptavia Diet Review 2024: Does This Program Really Work for Weight Loss?March 28, 2024 | finance.yahoo.comQ4 Rundown: BeautyHealth (NASDAQ:SKIN) Vs Other Personal Care StocksMarch 21, 2024 | finance.yahoo.comMEDIFAST (MED) Down 11.5% Since Last Earnings Report: Can It Rebound?March 20, 2024 | seekingalpha.comMedifast: Cheap Valuation, Uncertain FutureMarch 16, 2024 | finance.yahoo.comMED Apr 2024 20.000 putMarch 14, 2024 | finance.yahoo.comShould You Think About Buying Medifast, Inc. (NYSE:MED) Now?March 14, 2024 | seekingalpha.comLifeMD: Results And Guidance Point To Continued Strength In Weight Management ProgramMarch 13, 2024 | markets.businessinsider.comRobust Growth and Strategic Partnerships Reinforce Buy Rating for LifeMDMarch 12, 2024 | gurufocus.comDirector Scott Schlackman Sells Shares of Medifast Inc (MED)March 12, 2024 | msn.comLifeMD, Inc. (NASDAQ:LFMD) Q4 2023 Earnings Call TranscriptMarch 12, 2024 | finanznachrichten.deLifeMD, Inc.: LifeMD Reports Fourth Quarter 2023 ResultsMarch 8, 2024 | finance.yahoo.comMED Jun 2024 52.500 callMarch 7, 2024 | investorplace.comHey, Bottom Fishers! 3 Beaten Up Stocks to Buy for Short-Term GainsMarch 7, 2024 | seekingalpha.comMedifast Is Getting AttractiveSee More Headlines Receive MED Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medifast and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/20/2024Today4/18/2024Next Earnings (Confirmed)4/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorConsumer Staples Industry Miscellaneous food preparations & kindred products Sub-IndustryPersonal Products Current SymbolNYSE:MED CUSIP58470H10 CIK910329 Webwww.medifast1.com Phone(410) 581-8042Fax410-581-8070Employees634Year FoundedN/APrice Target and Rating Average Stock Price Target$61.00 High Stock Price Target$82.00 Low Stock Price Target$40.00 Potential Upside/Downside+87.7%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$9.11 Trailing P/E Ratio3.57 Forward P/E Ratio9.13 P/E GrowthN/ANet Income$99.42 million Net Margins9.27% Pretax Margin12.01% Return on Equity56.06% Return on Assets33.14% Debt Debt-to-Equity RatioN/A Current Ratio2.43 Quick Ratio1.84 Sales & Book Value Annual Sales$1.07 billion Price / Sales0.33 Cash Flow$10.94 per share Price / Cash Flow2.97 Book Value$18.50 per share Price / Book1.76Miscellaneous Outstanding Shares10,900,000Free Float10,672,000Market Cap$354.25 million OptionableOptionable Beta1.14 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Daniel R. Chard (Age 59)Executive Chairman & CEO Comp: $1.94MMr. James P. Maloney CPA (Age 56)Chief Financial Officer Comp: $823.91kMr. Anthony E. Tyree (Age 59)Chief Business Operations Officer Comp: $655.86kMr. Jason L. Groves Esq. (Age 53)Executive VP, General Counsel & Corporate Secretary Comp: $669.51kMr. Nicholas M. Johnson (Age 44)Chief Field Operations Officer Comp: $696.4kMr. Jonathan Barrett MacKenzie (Age 52)VP of Finance & Chief Accounting Officer Mr. Steven ZenkerVice President of Investor RelationsMs. Claudia C. Greninger (Age 51)Chief Human Resources Officer More ExecutivesKey CompetitorsCarriage ServicesNYSE:CSVCibusNASDAQ:CBUSLimoneiraNASDAQ:LMNRYatsenNYSE:YSGSeneca FoodsNASDAQ:SENEAView All CompetitorsInsiders & InstitutionsAllspring Global Investments Holdings LLCBought 30,610 shares on 4/18/2024Ownership: 0.394%Aviance Capital Partners LLCBought 1,506 shares on 4/18/2024Ownership: 0.080%DGS Capital Management LLCBought 10,477 shares on 4/15/2024Ownership: 0.096%Rowlandmiller & PARTNERS.ADVSold 3,733 shares on 4/8/2024Ownership: 0.027%Chickasaw Capital Management LLCSold 700 shares on 4/5/2024Ownership: 0.167%View All Insider TransactionsView All Institutional Transactions MED Stock Analysis - Frequently Asked Questions Should I buy or sell Medifast stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medifast in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" MED shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MED, but not buy additional shares or sell existing shares. View MED analyst ratings or view top-rated stocks. What is Medifast's stock price target for 2024? 2 equities research analysts have issued 12 month target prices for Medifast's stock. Their MED share price targets range from $40.00 to $82.00. On average, they expect the company's stock price to reach $61.00 in the next year. This suggests a possible upside of 87.7% from the stock's current price. View analysts price targets for MED or view top-rated stocks among Wall Street analysts. How have MED shares performed in 2024? Medifast's stock was trading at $67.22 at the beginning of 2024. Since then, MED stock has decreased by 51.7% and is now trading at $32.50. View the best growth stocks for 2024 here. Are investors shorting Medifast? Medifast saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 2,660,000 shares, an increase of 29.8% from the March 15th total of 2,050,000 shares. Based on an average daily trading volume, of 384,900 shares, the days-to-cover ratio is currently 6.9 days. Approximately 25.1% of the shares of the stock are short sold. View Medifast's Short Interest. When is Medifast's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, April 29th 2024. View our MED earnings forecast. How can I listen to Medifast's earnings call? Medifast will be holding an earnings conference call on Monday, April 29th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 844-512-2921 with passcode "13745406". How were Medifast's earnings last quarter? Medifast, Inc. (NYSE:MED) issued its earnings results on Tuesday, February, 20th. The specialty retailer reported $1.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.99 by $0.10. The specialty retailer had revenue of $191.02 million for the quarter, compared to analyst estimates of $184.17 million. Medifast had a net margin of 9.27% and a trailing twelve-month return on equity of 56.06%. The business's revenue for the quarter was down 43.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.70 earnings per share. How often does Medifast pay dividends? What is the dividend yield for Medifast? Medifast announced a quarterly dividend on Thursday, September 7th. Investors of record on Tuesday, September 19th will be paid a dividend of $1.65 per share on Tuesday, November 7th. This represents a $6.60 annualized dividend and a yield of 20.31%. The ex-dividend date of this dividend is Monday, September 18th. Read our dividend analysis for MED. Is Medifast a good dividend stock? Medifast (NYSE:MED) pays an annual dividend of $6.60 per share and currently has a dividend yield of 0.00%. The company does not yet have a strong track record of dividend growth. The dividend payout ratio is 72.45%. This payout ratio is at a healthy, sustainable level, below 75%. Based on EPS estimates, MED will have a dividend payout ratio of 132.00% in the coming year. This indicates that the company may not be able to sustain their current dividend. Read our dividend analysis for MED. What ETFs hold Medifast's stock? ETFs with the largest weight of Medifast (NYSE:MED) stock in their portfolio include Invesco S&P SmallCap High Dividend Low Volatility ETF (XSHD), Invesco S&P SmallCap Consumer Staples ETF (PSCC), WisdomTree U.S. SmallCap Quality Dividend Growth Fund (DGRS) and Global X Health & Wellness ETF (BFIT). What guidance has Medifast issued on next quarter's earnings? Medifast updated its first quarter 2024 earnings guidance on Tuesday, February, 20th. The company provided earnings per share (EPS) guidance of 0.250-0.950 for the period, compared to the consensus earnings per share estimate of 1.490. The company issued revenue guidance of $155.0 million-$175.0 million, compared to the consensus revenue estimate of $205.8 million. What is Daniel Chard's approval rating as Medifast's CEO? 44 employees have rated Medifast Chief Executive Officer Daniel Chard on Glassdoor.com. Daniel Chard has an approval rating of 93% among the company's employees. This puts Daniel Chard in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Medifast own? Based on aggregate information from My MarketBeat watchlists, some companies that other Medifast investors own include NVIDIA (NVDA), Alibaba Group (BABA), AbbVie (ABBV), Home Depot (HD), Boeing (BA), Johnson & Johnson (JNJ), Intel (INTC), Cisco Systems (CSCO), AT&T (T) and Exxon Mobil (XOM). Who are Medifast's major shareholders? Medifast's stock is owned by many different institutional and retail investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.39%), Chickasaw Capital Management LLC (0.17%), DGS Capital Management LLC (0.10%), Aviance Capital Partners LLC (0.08%) and Rowlandmiller & PARTNERS.ADV (0.03%). Insiders that own company stock include Andrea B Thomas, Constance J Hallquist, Constance J Hallquist, Daniel R Chard, Jeffrey J Brown, Jeffrey J Brown, Kevin G Byrnes and Scott Schlackman. View institutional ownership trends. How do I buy shares of Medifast? Shares of MED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:MED) was last updated on 4/19/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe “Perfect Storm” for GoldGold Safe ExchangeBiden’s $374B Giveaway Into This SectorDTIYour Money is Not SafeAmerican AlternativeThe #1 Crypto for 2024InvestorPlaceHe Is Giving Away BitcoinCrypto Swap ProfitsThe "Smart Money" Is Ready for May 1st Are You?Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medifast, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.